Research programme: VLP-based viral vaccines - Novavax

Drug Profile

Research programme: VLP-based viral vaccines - Novavax

Alternative Names: Rabies vaccine - Novavax

Latest Information Update: 09 Oct 2013

Price : $50

At a glance

  • Originator Novavax
  • Class Protein-vaccines; Recombinant fusion proteins; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Rabies

Most Recent Events

  • 09 May 2013 Preclinical trials in Rabies (prevention) in USA (Parenteral)
  • 01 May 2012 Early research is ongoing in USA
  • 06 Mar 2007 Early research in Viral infections (prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top